Post-earnings recap
Reported
Mon, May 10, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a larger-than-expected loss per share, which contributed to a 5.72% decline in their stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term prospects. Management's cautious tone suggests they are facing significant challenges, particularly in the competitive biotech landscape.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.69 | N/A | -33.46% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions affecting their financial performance. They reiterated their commitment to advancing their pipeline despite the losses.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in research and development.
The team acknowledged the competitive landscape in the biotech sector.